Priyanka Jain, co-founder and chief executive of Evvy, announced that the company has closed a $40 million Series B financing round. The round was led by Catalio Capital Management, a firm that backs innovative diagnostics. The funding will be used to transform Evvy's database of 100,000 patients' vaginal microbiomes into a research engine for women's health.
Why the funding matters
Evvy first entered the market as a consumer brand offering at-home tests for conditions such as urinary-tract infections and perimenopause. Over five years it has amassed a unique dataset that researchers believe can shed light on a wide range of health issues. The company's own data, combined with growing scientific interest in the vaginal microbiome, positions it to answer questions that have so far been difficult to study at scale.
There's so much third-party research showing that the vaginal microbiome plays a role in so much of women's health, and we finally have built the dataset to really answer those questions.
Jain explained that the new capital will allow Evvy to move beyond consumer testing and into the biotech arena, starting with fertility. By partnering with IVF clinics, the firm hopes to identify microbial markers that predict implantation success or failure, potentially improving outcomes for patients undergoing assisted reproduction.
What happens next
Beyond the research focus, Evvy plans to scale its consumer brand, targeting distribution through doctors' offices and other clinical settings. The founders noted that investors were initially split on whether the company should remain a pure consumer brand or become a data-driven biotech. Jain said the funding round required "a lot of education" of growth-stage investors who are still catching up with the women's health category.
With the Series B secured, Evvy will validate ongoing studies, expand its fertility-focused projects, and continue to grow its retail presence. The company's dual strategy aims to prove that a consumer health brand can also serve as a powerful research platform, potentially attracting further investment as the sector matures.